Darbepoetin Alfa
Darbepoetin alfa (recombinant DNA-produced 165-amino acid glycoprotein)
Also known as: Aranesp · Nespo · novel erythropoiesis stimulating protein · darbepoetina · darbepoetinum · Darbepoetin alfa · rhEPO derivative
Reviewed by the VetSheet Veterinary TeamUpdated Apr 5, 2026Evidence-based veterinary reference
Doses are a clinical reference for licensed veterinary professionals. Always confirm against the current label and the individual patient.
Dosing by species
🌎 NA — North America🌍 EU — Europe
Dogs
| Indication | Dose | Route | Frequency | Duration | Region |
|---|---|---|---|---|---|
| Anemia of chronic kidney disease | 0.45 micrograms/kg | SC/IV | once weekly | — | 🌎 NA |
- Anemia of chronic kidney disease: Initial human dose. Adjust using clinical judgment and careful monitoring. Alternatively, convert from epoetin alfa: Total weekly dose of epoetin in Units divided by 200 = once weekly dose in micrograms darbepoetin.
Cats
| Indication | Dose | Route | Frequency | Duration | Region |
|---|---|---|---|---|---|
| Anemia of chronic kidney disease | 0.45 micrograms/kg | SC/IV | once weekly | — | 🌎 NA |
- Anemia of chronic kidney disease: Initial human dose. Adjust using clinical judgment and careful monitoring. Alternatively, convert from epoetin alfa: Total weekly dose of epoetin in Units divided by 200 = once weekly dose in micrograms darbepoetin.
Doses are a clinical reference for licensed veterinary professionals. Always confirm against the current label and the individual patient.
Overview
Darbepoetin alfa is a synthetic, long-acting erythropoiesis-stimulating agent (ESA). It is a 165-amino acid protein produced via recombinant DNA technology in Chinese hamster ovary cells.
Clinical Pearl: Compared to epoetin alfa (rHuEPO), darbepoetin contains two additional N-linked carbohydrate chains. This structural modification increases its molecular weight and dramatically increases its metabolic stability and half-life, allowing for less frequent dosing (e.g., once weekly instead of three times weekly).
It is primarily used off-label in veterinary medicine to manage non-regenerative anemia associated with chronic kidney disease (CKD) in dogs and cats. Theoretically, the extra carbohydrate shielding may make it less immunogenic than epoetin alfa, potentially reducing the risk of pure red cell aplasia (PRCA), though this remains unproven in veterinary patients.
Mechanism of action
Darbepoetin alfa mimics endogenous erythropoietin by binding to the erythropoietin receptor (EpoR) on the surface of erythroid progenitor stem cells in the bone marrow.
- Binding induces receptor dimerization → activates the JAK2/STAT5 intracellular signaling pathway.
- This cascade → inhibits apoptosis of progenitor cells → stimulates their proliferation and differentiation into mature red blood cells (RBCs).
- The increased RBC mass subsequently raises the packed cell volume (PCV) and improves tissue oxygenation.
Safety & warnings
Contraindications
- Patients with documented anti-rHuEPO antibodies
- Uncontrolled hypertension
- Hypersensitivity to darbepoetin or excipients in the formulation
Adverse effects
- Anti-rHuEPO antibody formation leading to pure red blood cell aplasia (PRCA)
- Hypertension
- Seizures
- Iron deficiency (due to rapid RBC production depleting iron stores)
Precautions
Use with extreme caution in patients with pre-existing hypertension; blood pressure must be monitored. Monitor closely for the development of anti-rHuEPO antibodies, which is diagnosed by a sudden, severe drop in PCV, a high myeloid:erythroid ratio on bone marrow cytology, and the exclusion of other causes of anemia. Ensure adequate iron stores prior to and during therapy, as rapid erythropoiesis can quickly deplete iron.
Drug interactions
May increase the sensitivity of erythroid progenitors (interaction has been used for therapeutic effect with epoetin)
Can decrease bleeding times when used concurrently with erythropoietin agents
Monitoring
- PCV/Hematocrit (check before each re-dosing)
- Iron stores (supplement with iron if necessary)
- Blood pressure
Pharmacokinetics
Absorption
Humans (SC): Bioavailability is about 37% and the drug is absorbed slowly.
Distribution
Humans: Distribution half-life is about 1.4 hours.
Metabolism
Extensively metabolized.
Elimination
Humans: Terminal elimination half-life averages 21 hours (about 3 times greater than that of epoetin alfa).
Overdose
Little information is available in veterinary species. In humans, therapeutic dosages of up to 8 micrograms/kg every week for 12 weeks have been administered. Polycythemia (excessive red blood cells) is possible with overdosage, and therapeutic phlebotomy may be required to reduce blood viscosity.
Available products
Formulations
- Injection solution (polysorbate or albumin-based)
- Prefilled syringes
Human-labeled
- Darbepoetin Alfa Solution for Injection (preservative free); Aranesp®: 25 mcg/0.42 mL, 40 mcg/0.4 mL, 60 mcg/0.3 mL, 100 mcg/0.5 mL, 150 mcg/0.3 mL, 200 mcg/0.4 mL, 300 mcg/0.6 mL in single-dose prefilled syringes
- Darbepoetin Alfa Solution for Injection (preservative free); Aranesp®: 25 mcg/mL, 40 mcg/mL, 60 mcg/mL, 100 mcg/mL, 150 mcg/0.75 mL, 200 mcg/mL, 300 mcg/mL, 500 mcg/mL in single-dose vials
Regulatory status
POM (Prescription Only Medicine). Human product used under the cascade.
POM (Prescription Only Medicine). Human product used under the cascade.
No regulatory data for: 🇺🇸 US · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
Storage & stability
Store at 2-8°C (36-46°F) and protect from light. Do not freeze or shake the vials or syringes.
Client information
Important: This medication is used to treat severe anemia caused by chronic kidney disease. It helps the body produce more red blood cells but is not a cure for the underlying kidney disease.
- Patience is required: Therapeutic effects may not be noted for several weeks after starting treatment. Do not expect an immediate increase in energy.
- Commitment: Treatment requires a significant financial commitment, as the drug is expensive.
- Frequent Monitoring: Your pet will need regular veterinary visits to check their red blood cell count (PCV), iron levels, and blood pressure.
- Watch for Side Effects: Contact your veterinarian immediately if you notice signs of high blood pressure (e.g., sudden blindness, behavioral changes, stumbling) or a sudden, severe drop in energy, which could indicate a rare immune reaction where the body stops making red blood cells entirely.
VetSheet drug reference is intended for licensed veterinary professionals as a clinical decision-support aid, not a substitute for professional judgement or the manufacturer’s current label.